Research Paper Volume 15, Issue 9 pp 3572—3585
Increased SEMA6B expression as a potential prognostic and immune cell infiltration biomarker in thyroid cancer patients
- 1 Department of Endocrinology, First Hospital of Handan City, Congtai, Handan 056002, Hebei Province, China
- 2 Department of Endocrinology, The First Medical Center, Chinese PLA General Hospital, Haidian, Beijing 100853, China
- 3 Department of Ultrasound Medicine, Handan Central Hospital, Congtai, Handan 056008, Hebei Province, China
- 4 Department of Neurology, Handan Central Hospital, Congtai, Handan 056008, Hebei Province, China
- 5 Physical Examination Center, Handan Central Hospital, Congtai, Handan 056008, Hebei Province, China
Received: February 6, 2023 Accepted: April 17, 2023 Published: May 5, 2023
https://doi.org/10.18632/aging.204691How to Cite
Copyright: © 2023 Lei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Even today, thyroid cancer (THCA) remains an important threat to global health. For THCA patients, differentiated thyroid cancer is the most commonly identified pathological subtype, and those diagnosed with papillary thyroid cancer generally have good overall prognosis. For poorly differentiated subtype THCA, patients have aggressive disease course, higher risk of distant organ metastasis and inferior overall prognosis.
Methods: RNA-seq data from TCGA and GTEx databases are collected and analyzed via R. The correlation between SEMA6B expression level and pathological as well as clinical parameters of THCA patients was respectively investigated. Gene expression profiling and subsequent functional clustering analysis was the performed utilizing GSEA. The receiver operating characteristic (ROC) curve was utilized to evaluate the diagnostic value of SEMA6B expression.
Results: Increased SEMA6B expression was characteristic in THCA tumor samples and was associated with specific pathologic and clinical features for TCHA patients. Univariate and multivariate analysis indicated that SEMA6B was independent predictive marker for THCA patients’ prognosis. Gene expression profiling and functional clustering analysis suggested that SEMA6B high-expression was related with increased expression of multiple signal pathways and signatures of multiple immune cell infiltration.
Conclusions: In this study, through bioinformatic analysis and clinical data investigation, we demonstrated the potential value of SEMA6B as diagnostic and prognostic marker in THCA patient treatment.